136 related articles for article (PubMed ID: 19877692)
1. Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).
Nolan KA; Doncaster JR; Dunstan MS; Scott KA; Frenkel AD; Siegel D; Ross D; Barnes J; Levy C; Leys D; Whitehead RC; Stratford IJ; Bryce RA
J Med Chem; 2009 Nov; 52(22):7142-56. PubMed ID: 19877692
[TBL] [Abstract][Full Text] [Related]
2. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.
Scott KA; Barnes J; Whitehead RC; Stratford IJ; Nolan KA
Biochem Pharmacol; 2011 Feb; 81(3):355-63. PubMed ID: 20970406
[TBL] [Abstract][Full Text] [Related]
4. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.
Asher G; Dym O; Tsvetkov P; Adler J; Shaul Y
Biochemistry; 2006 May; 45(20):6372-8. PubMed ID: 16700548
[TBL] [Abstract][Full Text] [Related]
5. Affinity-based small fluorescent probe for NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation.
Bian J; Li X; Xu L; Wang N; Qian X; You Q; Zhang X
Eur J Med Chem; 2017 Feb; 127():828-839. PubMed ID: 27829520
[TBL] [Abstract][Full Text] [Related]
6. Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.
Nolan KA; Zhao H; Faulder PF; Frenkel AD; Timson DJ; Siegel D; Ross D; Burke TR; Stratford IJ; Bryce RA
J Med Chem; 2007 Dec; 50(25):6316-25. PubMed ID: 17999461
[TBL] [Abstract][Full Text] [Related]
7. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
[TBL] [Abstract][Full Text] [Related]
8. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.
Nolan KA; Scott KA; Barnes J; Doncaster J; Whitehead RC; Stratford IJ
Biochem Pharmacol; 2010 Oct; 80(7):977-81. PubMed ID: 20599803
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of zeta-crystallin by Coumarins: a structure-activity study.
Duhaiman AS
J Protein Chem; 1996 Apr; 15(3):261-4. PubMed ID: 8804573
[TBL] [Abstract][Full Text] [Related]
11. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
[TBL] [Abstract][Full Text] [Related]
12. Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism.
Timson DJ
Curr Drug Targets; 2017; 18(5):500-510. PubMed ID: 26201483
[TBL] [Abstract][Full Text] [Related]
13. Aerobic Cytotoxicity of Aromatic
Nemeikaitė-Čėnienė A; Šarlauskas J; Misevičienė L; Marozienė A; Jonušienė V; Lesanavičius M; Čėnas N
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228195
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
[TBL] [Abstract][Full Text] [Related]
15. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
[TBL] [Abstract][Full Text] [Related]
16. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
Colucci MA; Reigan P; Siegel D; Chilloux A; Ross D; Moody CJ
J Med Chem; 2007 Nov; 50(23):5780-9. PubMed ID: 17944451
[TBL] [Abstract][Full Text] [Related]
18. Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.
Nolan KA; Humphries MP; Barnes J; Doncaster JR; Caraher MC; Tirelli N; Bryce RA; Whitehead RC; Stratford IJ
Bioorg Med Chem; 2010 Jan; 18(2):696-706. PubMed ID: 20036559
[TBL] [Abstract][Full Text] [Related]
19. Alkynyloxy derivatives of 5,8-quinolinedione: Synthesis, in vitro cytotoxicity studies and computational molecular modeling with NAD(P)H:Quinone oxidoreductase 1.
Kadela-Tomanek M; Jastrzębska M; Pawełczak B; Bębenek E; Chrobak E; Latocha M; Książek M; Kusz J; Boryczka S
Eur J Med Chem; 2017 Jan; 126():969-982. PubMed ID: 28006669
[TBL] [Abstract][Full Text] [Related]
20. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.).
Lienhart WD; Gudipati V; Uhl MK; Binter A; Pulido SA; Saf R; Zangger K; Gruber K; Macheroux P
FEBS J; 2014 Oct; 281(20):4691-4704. PubMed ID: 25143260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
